BACKGROUND: The aim of this study was to compare the extent of pathologic response in patients with HER2-positive (HER2+) breast cancer treated with standard neoadjuvant chemotherapy, with or without trastuzumab (H), according to hormone receptor (HR) status. PATIENTS AND METHODS: We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C). Residual cancer burden (RCB) was determined from pathologic review of the primary tumor and lymph nodes and was classified as pathologic complete response (pCR) or minimal (RCB-I), moderate (RCB-II), or extensive (RCB-III) residual disease. RESULTS: In HR-positive (HR+) cancers, a higher rate of pathologic response (pCR/RCB-I) was observed with concurrent H + 3-wP/FEC (73%) than with 3-wP/FEC (34%, P = 0.002) or wP/FAC (47%; P = 0.02) chemotherapy alone. In HR-negative (HR-) cancers, there were no significant differences in the rate of pathologic response (pCR/RCB-I) from 3-wP/FAC (50%), wP/FAC (68%), or concurrent H + 3-wP/FEC (72%). CONCLUSIONS: Patients with HR+/HER2+ breast cancer obtained significant benefit from addition of trastuzumab to P/FEC chemotherapy; pathologic response rate was similar to that seen in HR-/HER2+ breast cancers.
BACKGROUND: The aim of this study was to compare the extent of pathologic response in patients with HER2-positive (HER2+) breast cancer treated with standard neoadjuvant chemotherapy, with or without trastuzumab (H), according to hormone receptor (HR) status. PATIENTS AND METHODS: We included 199 patients with HER2+ breast cancer from three successive cohorts of neo-adjuvant chemotherapy on the basis of paclitaxel (Taxol) (P) administered weekly (w) or three weekly (3-w), followed by 5-fluorouracil (F), doxorubicin (A) or epirubicin (E), and cyclophosphamide (C). Residual cancer burden (RCB) was determined from pathologic review of the primary tumor and lymph nodes and was classified as pathologic complete response (pCR) or minimal (RCB-I), moderate (RCB-II), or extensive (RCB-III) residual disease. RESULTS: In HR-positive (HR+) cancers, a higher rate of pathologic response (pCR/RCB-I) was observed with concurrent H + 3-wP/FEC (73%) than with 3-wP/FEC (34%, P = 0.002) or wP/FAC (47%; P = 0.02) chemotherapy alone. In HR-negative (HR-) cancers, there were no significant differences in the rate of pathologic response (pCR/RCB-I) from 3-wP/FAC (50%), wP/FAC (68%), or concurrent H + 3-wP/FEC (72%). CONCLUSIONS:Patients with HR+/HER2+ breast cancer obtained significant benefit from addition of trastuzumab to P/FEC chemotherapy; pathologic response rate was similar to that seen in HR-/HER2+ breast cancers.
Authors: Syed K Mohsin; Heidi L Weiss; M Carolina Gutierrez; Gary C Chamness; Rachel Schiff; Michael P Digiovanna; Chun-Xia Wang; Susan G Hilsenbeck; C Kent Osborne; D Craig Allred; Richard Elledge; Jenny C Chang Journal: J Clin Oncol Date: 2005-02-14 Impact factor: 44.544
Authors: W F Symmans; M D Volm; R L Shapiro; A B Perkins; A Y Kim; S Demaria; H T Yee; H McMullen; R Oratz; P Klein; S C Formenti; F Muggia Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: D J Slamon; B Leyland-Jones; S Shak; H Fuchs; V Paton; A Bajamonde; T Fleming; W Eiermann; J Wolter; M Pegram; J Baselga; L Norton Journal: N Engl J Med Date: 2001-03-15 Impact factor: 91.245
Authors: Marjorie C Green; Aman U Buzdar; Terry Smith; Nuhad K Ibrahim; Vicente Valero; Marguerite F Rosales; Massimo Cristofanilli; Daniel J Booser; Lajos Pusztai; Edgardo Rivera; Richard L Theriault; Cynthia Carter; Debra Frye; Kelly K Hunt; W Fraser Symmans; Eric A Strom; Aysegul A Sahin; William Sikov; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Catharina Wenzel; Dagmar Hussian; Rupert Bartsch; Ursula Pluschnig; Gottfried J Locker; Margarethe Rudas; Michael F Gnant; Raimund Jakesz; Christoph C Zielinkski; Guenther G Steger Journal: J Cancer Res Clin Oncol Date: 2004-07 Impact factor: 4.553
Authors: Harold J Burstein; Lyndsay N Harris; Rebecca Gelman; Susan C Lester; Raquel A Nunes; Carolyn M Kaelin; Leroy M Parker; Leif W Ellisen; Irene Kuter; Michele A Gadd; Roger L Christian; Patricia Rae Kennedy; Virginia F Borges; Craig A Bunnell; Jerry Younger; Barbara L Smith; Eric P Winer Journal: J Clin Oncol Date: 2003-01-01 Impact factor: 44.544
Authors: Laura J Esserman; Donald A Berry; Angela DeMichele; Lisa Carey; Sarah E Davis; Meredith Buxton; Cliff Hudis; Joe W Gray; Charles Perou; Christina Yau; Chad Livasy; Helen Krontiras; Leslie Montgomery; Debasish Tripathy; Constance Lehman; Minetta C Liu; Olufunmilayo I Olopade; Hope S Rugo; John T Carpenter; Lynn Dressler; David Chhieng; Baljit Singh; Carolyn Mies; Joseph Rabban; Yunn-Yi Chen; Dilip Giri; Laura van 't Veer; Nola Hylton Journal: J Clin Oncol Date: 2012-05-29 Impact factor: 44.544
Authors: W Fraser Symmans; Caimiao Wei; Rebekah Gould; Xian Yu; Ya Zhang; Mei Liu; Andrew Walls; Alex Bousamra; Maheshwari Ramineni; Bruno Sinn; Kelly Hunt; Thomas A Buchholz; Vicente Valero; Aman U Buzdar; Wei Yang; Abenaa M Brewster; Stacy Moulder; Lajos Pusztai; Christos Hatzis; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2017-01-30 Impact factor: 44.544
Authors: Laura S Dominici; Viviana M Negron Gonzalez; Aman U Buzdar; Anthony Lucci; Elizabeth A Mittendorf; Huong T Le-Petross; Gildy V Babiera; Funda Meric-Bernstam; Kelly K Hunt; Henry M Kuerer Journal: Cancer Date: 2010-06-15 Impact factor: 6.860
Authors: Edith A Perez; Monica M Reinholz; David W Hillman; Kathleen S Tenner; Matthew J Schroeder; Nancy E Davidson; Silvana Martino; George W Sledge; Lyndsay N Harris; Julie R Gralow; Amylou C Dueck; Rhett P Ketterling; James N Ingle; Wilma L Lingle; Peter A Kaufman; Daniel W Visscher; Robert B Jenkins Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544
Authors: D Rossi; B Pistilli; D Morale; V Casadei; G Benedetti; P Alessandroni; V Catalano; P Giordani; F Graziano; S Luzi Fedeli; G Fiorentini Journal: World J Oncol Date: 2011-10-28